Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute myeloid leukemia.

Jeffrey E Rubnitz1, Brenda Gibson, Franklin O Smith

  • 1Department of Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA. jeffrey.rubnitz@stjude.org

Pediatric Clinics of North America
|February 5, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunophenotypic, Cytogenetic, and Molecular Characterization of NUP98-Rearranged Pediatric Myeloid Neoplasms.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Novel <i>KAT6B::NUTM2B</i> fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy.

Haematologica·2026
Same author

Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.

British journal of haematology·2026
Same author

Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study.

The Lancet. Microbe·2026
Same author

Population pharmacokinetics and dose-response relationships of mitoxantrone in children with acute myeloid leukaemia.

British journal of clinical pharmacology·2026
Same author

Clonal Evolution of Pediatric Acute Myeloid Leukemia and Its Contribution to Disease Relapse.

medRxiv : the preprint server for health sciences·2025
Same journal

Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

Pediatric clinics of North America·2026
Same journal

Advancing Pediatric Dermatology: Innovations in Care and Access.

Pediatric clinics of North America·2026
Same journal

No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

Pediatric clinics of North America·2026
Same journal

Telemedicine and Access to Pediatric Dermatology Care.

Pediatric clinics of North America·2026
Same journal

Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

Pediatric clinics of North America·2026
Same journal

Medical Photography's Power to Change Medical Care.

Pediatric clinics of North America·2026
See all related articles

Pediatric acute myeloid leukemia (AML) survival has improved due to collaborative research. Future progress relies on understanding AML biology and developing targeted therapies alongside chemotherapy.

Area of Science:

  • Hematology
  • Pediatric Oncology
  • Cancer Genetics

Background:

  • Acute myeloid leukemia (AML) is a complex blood cancer originating from hematopoietic precursors.
  • Genetic mutations and chromosomal rearrangements drive AML development.
  • Significant advancements in pediatric AML treatment have been achieved over the last 30 years.

Purpose of the Study:

  • To summarize the current state of pediatric acute myeloid leukemia (AML) treatment and survival.
  • To highlight the importance of understanding AML biology for future therapeutic development.

Main Methods:

  • Review of collaborative clinical research findings in pediatric AML.
  • Analysis of survival data over the past three decades.

Main Results:

Related Experiment Videos

  • Disease-free survival rates in children with AML have markedly improved.
  • Collaborative international research efforts have been crucial to these improvements.

Conclusions:

  • Continued progress in understanding AML biology is essential for further enhancing patient outcomes.
  • Development of novel molecularly targeted agents, used in conjunction with standard chemotherapy, holds promise for future AML treatment strategies.